Glecaprevir/pibrentasvir

Property	Value
rdf:type	World Health Organization essential medicine owl:NamedIndividual Combination drug NS5A inhibitor NS3/4A protease inhibitor AbbVie brand Drug granted breakthrough therapy designation
rdfs:label	Glecaprevir/pibrentasvir
owl:sameAs	dbr:Glecaprevir/pibrentasvir
prov:wasDerivedFrom	http://en.wikipedia.org/wiki/Category:NS5A_inhibitors http://en.wikipedia.org/wiki/Category:World_Health_Organization_essential_medicines http://en.wikipedia.org/wiki/WHO_Model_List_of_Essential_Medicines http://en.wikipedia.org/wiki/Category:NS3/4A_protease_inhibitors http://en.wikipedia.org/wiki/Category:Combination_drugs http://en.wikipedia.org/wiki/List_of_drugs_granted_breakthrough_therapy_designation http://en.wikipedia.org/wiki/Category:AbbVie_brands
skos:prefLabel	Glecaprevir/pibrentasvir
skos:altLabel	Glecaprevir and pibrentasvir Glecaprevir/Pibrentasvir Mavyret/Maviret (glecaprevir/pibrentasvir) glecaprevir/pibrentasvir
clgo:alternativeName	Mavyret, Maviret, others
clgo:kegg	D11014
clgo:medlinePlus	a617039
is clgo:product of	AbbVie

About: clgr:Glecaprevir/pibrentasvir